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Abstract. This study aims to evaluate immunization with polymeric microparticles containing recombinant
antigen 85B (rAg85B) delivered directly to the lungs to protect against tuberculosis. rAg85Bwas expressed in
Escherichia coli and encapsulated in poly(lactic-co-glycolic acid) microparticles (P-rAg85B). These were
delivered as dry powders to the lungs of guinea pigs in single or multiple doses of homologous and
heterologous antigens. Bacille Calmette–Guérin (BCG) delivered subcutaneously was employed as the
positive control and as part of immunization strategies. Immunized animals were challenged with a low-dose
aerosol of Mycobacterium tuberculosis (MTB) H37Rv to assess the extent of protection measured as
reduction in bacterial burden (CFU) in the lungs and spleens of guinea pigs. Histopathological examination
andmorphometric analysis of these tissues were also performed. The heterologous strategy of BCG prime–P-
rAg85B aerosol boosts appeared to enhance protection frombacterial infection, as indicated by a reduction in
CFU in both the lungs and spleens compared with untreated controls. Although the CFU data were not
statistically different from the BCG andBCG–BCGgroups, the histopathological andmorphometric analyses
indicated the positive effect of BCG–P-rAg85B in terms of differences in area of tissue affected and number
and size of granulomas observed in tissues. P-rAg85B microparticles appeared to be effective in boosting a
primary BCG immunization against MTB infection, as indicated by histopathology and morphometric
analysis. These encouraging observations are relevant to boosting adults previously immunized with BCG or
exposed toMTB, commonly the case in the developing world, and should be followed by further assessment
of an appropriate immunization protocol for maximum protection.
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INTRODUCTION
Tuberculosis (TB) is the leading cause of death from a
single infectious pathogen. Approximately 1.6 million people
died of this disease in 2005 (1). Currently, the only approved
TB vaccine is the attenuated strain of Mycobacterium bovis,
Bacillus Calmette–Guérin (BCG). However, the protective
effect of this vaccine has been shown to be highly variable
and diminishes 10–15 years following administration (2).
Therefore, new vaccines and immunizations strategies are
needed urgently to prevent TB infection.
Since the majority of TB patients acquire their primary
infection by the pulmonary route, vaccine administration to
the lungs may elicit an immunologically relevant response
resulting in protection from infection (3). Alveolar macro-
phages are antigen presenting, host cells for Mycobacterium
tuberculosis (MTB) in the lungs and the principal target for
antigen delivery. Depending on composition and physico-
chemical properties, particles <10 µm in aerodynamic diam-
eter may be inhaled as aerosols and deposit in the lungs (4).
They will reside at the site of deposition for extended periods
of time prior to uptake by antigen presenting cells (APCs)
(5). The combination of aerosol particle entry to the lungs
and their subsequent uptake by macrophages increases the
probability of eliciting a potent immune response (6). There-
fore, immunization by the pulmonary route is a promising
alternative to conventional approaches with a strong mecha-
nistic rationale for the likelihood of success.
Poly (lactic-co-glycolic acid) (PLGA) copolymers have
frequently been described as carriers for antigens (7,8).
PLGA microparticles, in diameters ranging from 1 to 10 μm
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and loaded with antigenic peptides, interact with APCs to
induce cell-mediated immunity (9,10). Antigen 85B (Ag85B),
a secreted protein from M. tuberculosis, is one of the most
promising vaccine candidates for prevention of tuberculosis.
It induces both humoral and cell-mediated immune responses
(CD4 and CD8 T cell responses) in MTB-infected patients
(11,12). The immunoprotective effect of Ag85B has been
demonstrated in the highly relevant low-dose aerosol inocula-
tion guinea pig model of pulmonary tuberculosis (13). Further-
more, the recombinant Ag85B (rAg85B) encapsulated in
respirable PLGA microparticles (designed P-rAg85B in this
study) enhanced the CD4 Th1 cell response after being
processed by human macrophage-like THP-1 cells and pre-
sented to the DB-1, T hybridoma cell, which recognizes an
epitope of Ag85B (14). Production of sufficient quantities of
Ag85B from bacterial cell cultures is limited, but the antigen can
be generated for vaccine development by recombinant methods
using Escherichia coli overexpression (15).
Antigen subunit proteins necessarily present a much
smaller number of epitopes required for immunization than
the original whole organism. This frequently results in a weak
immune response. In order to amplify the response, the
antigen may be administered several times in a regimen
designated a prime-boost immunization strategy. The boost
that follows the priming dose may be homologous or
heterologous which reflects dosing with the same or different
antigens to the prime, respectively. Repeated immunization
with the same antigen is expected to result in higher levels of
antibodies than following a single dose. Homologous boosting
is sufficient to protect from organisms where humoral
response is the dominant element of immunity (16). Many
pathogens, including MTB, need T cell-mediated responses
for protective immunity. Pathogen-specific T cells are induced
in higher levels in response to a heterologous, rather than a
homologous, boost in a variety of animal models of TB (16).
Moreover, adult populations in many developing countries
have been immunized previously with BCG or exposed to
MTB, which constitutes the priming exposure, and a boost
approach is more appropriate for these populations. There-
fore, there is a need to develop an effective boosting
immunization that could enhance and prolong the protective
immunity based on BCG, or prior MTB, initiated immunity.
The objective of the present study was to evaluate a
prime-boost immunization strategy with polymeric micro-
particles containing rAg85B delivered as aerosols to the lungs
in comparison or combination with BCG to protect against
tuberculosis.
MATERIALS AND METHODS
Recombinant Antigen 85B. rAg85B protein was pro-
duced from E. coli strain of JM109DE3, containing Ag85B
gene with His tag (courtesy of Dr. Douglas Kernodle,
Vanderbilt University). Flasks containing 1 L Luria–Bertani
broth and 50 μg of carbenicillin per milliliter were inoculated
with 20 ml of an overnight culture of E. coli JM109DE3 and
incubated at 37°C until the OD600 reading reached 0.4–0.5.
Recombinant protein expression was then induced by the
addition of isopropyl-β-thiogalactopyranoside (IPTG, 1 mM)
and incubation at 22°C overnight. The E. coli cells were
pelleted and then probe-sonicated. The supernatant was
passed through a nickel-affinity column (Ni Sepharose™ 6
Fast Flow, Amersham Biosciences, Piscataway, NJ). The
eluted fractions with His-tag proteins were further purified
in a Superdex 75 peptide column (Amersham Biosciences,
Piscataway, NJ) using Tris (20 mM, pH 7.5)–sodium chloride
(1 M), as the eluting buffer. The rAg85B was quantified at
UV 280 nm with extinction coefficient of UV280 of 1.0 for a
1.0 mg/mL protein solution (15).
Endotoxin in the protein preparations was removed with
Detoxin-Gel™EndotoxinRemovingGel (Pierce, Rockford, IL).
The endotoxin level was quantified by QCL-Chromogenic LAL
(Cambrex Bio Science Walkersville, Inc., Walkersville, MD) and
determined to be <0.025 ng/mg after purification. Proteins were
dialyzed in 0.1 M ammonium bicarbonate overnight and then
lyophilized for 48 h.
Microparticle Manufacture. PLGA polymer (700 mg;
MW 84.7 kDa, L/G 75:25, intrinsic viscosity 0.68 dL/g in
chloroform, Durect Corp., Pelham, AL) was dissolved in
200 ml methylene chloride (organic phase). The aqueous
phase consisted of either 4 or 16 mg rAg85B dissolved in
2.4 ml of 20 mM sodium phosphate buffer, pH 7.4 with or
without trehalose dibehenate (TDB, Sigma, St. Louis, MO), a
component of the MTB cell wall, the molecular structure, and
adjuvancy is well documented (17). The aqueous and organic
phases were probe-sonicated for three 10-s periods on an ice
bath immediately prior to spray drying. Microparticles were
manufactured using a spray-drier (Buchi Mini Spray-drier B-
191, Buchi, Flawil, Switzerland) with optimized conditions of
liquid feed rate 4.5 mL/min, atomization pressure 3.0 bar,
inlet temperature 65°C, outlet temperature 41–43°C, and
nitrogen flow 600 L/h.
Encapsulation Efficiency and Antigen Stability. The
amount of rAg85B was determined as follows: Two milliliter
of DMSO was added to a vial containing 10–20 mg of P-
rAg85B microspheres and periodical stirring for an hour. Ten
milliliter of 0.05 N NaOH with 0.5% SDS was then added, and
the contents of the vial gently mixed and let stand for 1 h. The
contents of the vial were centrifuged (10 min, 12,000 rpm, 4°C)
and the supernatant assayed for protein content of Ag85B by
Lowry’s method. The functionality of rAg85B after particle
manufacture was evaluated by the T hybridoma cell recognition
assay (14).
Aerodynamic Performance of PLGA Microparticles. The
aerodynamic performance of the microparticles when deliv-
ered from an Insufflator DP-3 (Penncentury, PA) was
evaluated with the USP apparatus B and the nonviable
Andersen cascade impactor (ACI) under a vacuum of
60LPM for 4 s. Emitted dose was determined by the USP
apparatus B, whereas the mass median aerodynamic diameter
(MMAD) and the fine particle fractions (fraction of the
particles sizing <5 μm in emitted dose) were calculated after
powder evaluation with the ACI.
Animals. Dunkin-Hartley guinea pigs weighing 368.9 ±
19.4 g were employed (Hilltop Laboratory Animals, Inc.,
Scottsdale, PA). The animals were housed in a 12-h light/12-h
dark cycle and constant temperature environment of 22°C with
free access to food and water. All animal protocols were
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approved by the Institutional Animal Care and Use Committee
of the University of North Carolina at Chapel Hill.
Aerosol Immunization. Immunization regimens con-
sisted of single and multiple-dosed groups and are shown in
Fig. 1. Five groups (n=6) were employed in a single-dose
regimen: BCG (1 × 103CFU, Tice strain, Organon USA Inc.,
Roseland, NJ) was subcutaneously (s.c.) administered to
guinea pigs as positive control; negative controls consisted
of untreated animals and those treated with PLGA
microparticles alone; PLGA-rAg85B (P-rAg85B, 0.57% w/w
rAg85B) and PLGA-rAg85B-TDB (P-rAg85B-TDB, 0.57%
w/w rAg85B, 0.1% w/w TDB) were the microparticle vaccine
formulations, containing subunit antigens, administered by
insufflation as follows. Animals were anesthetized with a
mixture of ketamine (50 mg/kg), xylazine (5 mg/kg), intubated
and approximately 10 mg of microparticle formulations were
administered with a small animal insufflator (Model DP-3, Penn
Century, PA) into the airways of guinea pigs. In a multiple-dose
regimen, the animals were primed with P-rAg85B (0.57% w/w
r-Ag85B, 10 mg by insufflation), P-rAg85B-TDB (0.57% w/w
rAg85B, 0.1% w/w TDB, 10 mg by insufflation), and BCG
(s.c. 1 × 103CFU). Animals were boosted 4 weeks later by
insufflation with approximately 10 mg of P-rAg85B (0.57% w/w
r-Ag85B, for P-rAg85B and BCG groups) and P-rAg85B-TDB
(0.57% w/w rAg85B, 0.1% w/w TDB, for P-rAg85B-TDB
group), or BCG (s.c. 1 × 103CFU). The second boosting dose
was administered 10 weeks after initial prime vaccination by
insufflation of approximately 3 mg of P-rAg85B (2.28% w/w
rAg85B; for P-rAg85B and BCG groups) and P-rAg85B-TDB
(2.28% w/w rAg85B, 0.1% w/w TDB; for P-rAg85B-TDB
group). The schedule for aerosol immunization in multiple-
dose groups was selected based on previous studies employing
BCG and Ag85B (13,18,19). Animal weights were recorded
throughout the study.
Cutaneous Delayed-Type Hypersensitivity. Intradermal
injection of purified protein derivative (PPD) allows the
detection of individuals sensitized by mycobacteria, either
due to TB infection (20) or to assess the degree of immunity
conferred by BCG vaccine (21). Upon inoculation into the
skin of sensitized individuals, a delayed-type hypersensitivity
(DTH) response is evoked (22). This test was performed in
immunized animals, the day prior to bacterial challenge. PPD
(100TU, from MTB H37Rv, Mycos Research, Loveland, CO)
and rAg85B (50 μg in 100 μl phosphate-buffered saline
(PBS)) were injected intradermally (i.d.) on the two flanks
of the animals. The injection sites were measured with a pair
of calipers 24 h after i.d. injection for mean diameter of
induration or erythema. It should be noted that the gene
sequence for very few guinea pig cytokines and chemokines are
available (23). Consequently, insufficient reagents exist to
conduct a thorough assessment of immunogenicity as would be
familiar to those working with other species for which many
cytokine ELISA assays are commercially available (24–26).
Bacterial Challenge with MTB H37Rv. A whole body
exposure chamber was employed for bacterial challenge of
the immunized animals by inhalation. A nebulizer (Collison,
Venturi unit, Waltham, MA) was employed to atomize the
suspension of MTB, strain H37Rv (ATCC, Manassas, VA), at
a concentration of 5 × 104CFU in PBS, mixed with secondary
air prior to delivery to an exposure chamber (University of
Wisconsin, Mechanical Engineering Workshop, Madison, WI)
under vacuum (27,28). After 5 min of nebulization of the
bacterial suspension, the primary air supply was stopped and
airflow through the chamber continued for 10 min. This
procedure, has been shown to result in the inhalation and
retention of 10–15 viable virulent microorganisms in the lungs
of guinea pigs (29,30).
Necropsy and Bacteriology. Necropsy was performed
4 weeks after bacterial challenge when the bacterial burden
is known to plateau in the lungs of infected animals (31).
Guinea pigs were euthanized with a lethal dose of sodium
pentobarbital (175 mg/kg) and exsanguinated prior to nec-
ropsy. The peritoneal and chest cavities were exposed and
lungs resected, weighed, and inspected for grossly visible
primary lesions. Spleen and liver were also resected asepti-
cally and the weight recorded, as an indirect measurement of
the degree of inflammation. The lower left lobe of the lung
and a piece of the spleen were homogenized separately using
Teflon glass homogenizers. Tissue homogenates were diluted
with sterile saline, and aliquots were inoculated onto dupli-
cate Middlebrook 7H10 agar plates. After being sealed with
oxygen permeable tape, plates were incubated at 37°C, and
Fig. 1. Immunization regimens for single and multiple-dosed groups
340 Lu et al.
the number of bacterial colonies (CFU) was counted after
21 days. Bacteriology is reported as Log10 protection=[(CFU/ml
untreated control)−(CFU/ml treatment)].
Histopathological analysis. In the day of necropsy, the
right lower lung lobe and a portion of the spleen were
preserved in 10% neutral-buffered formalin solution. These
tissues were later embedded in paraffin and sectioned with a
microtome (Leica Microsystems, Bannockburn, IL, USA) at
5 mm. The sections were mounted on a glass slide and stained
with hematoxylin–eosin for microscopic evaluation by a
pathologist that was blinded with respect to the treatments
received by each group.
For selected treatment groups, the area of each tissue
affected by granulomas was further quantified by morphometric
analysis. The internal structure of “true granulomas” containing
a central core of aggregated histiocytes (and in some cases
degenerate neutrophils) surrounded by a band of lymphocytes
was measured using “ImageJ” software (Rasband, W.S.,
ImageJ, US National Institutes of Health, Bethesda, Maryland,
USA, http://rsb.info.nih.gov/ij/, 1997–2008). Image measure-
ments were calibrated with a certified stage micrometer
provided by Klarmann Rulings, Inc. Data points were sub-
sequently entered into an Excel spreadsheet where the total
area of individual granulomas was calculated and reported in
square meters.
Statistics. One-way ANOVA and the least-squares sig-
nificant difference multiple comparison method were used to
compare the multiple groups. The statistical significance was
set at p<0.05.
RESULTS
Microparticle Manufacture and Characterization
PLGA, P-rAg85, and P-rAg85B-TDB microspheres were
manufactured under optimized conditions as described pre-
viously (14). The resulting microspheres had porous structure
with an encapsulation efficiency of 91.3% for rAg85B. The
antigen appeared to be functional after spray drying of
microspheres as evidenced by their ability to induce DB-1
cells to produce IL-2 in the T hybridoma cell recognition
assay (14). The emitted dose was determined to be 92.9%
(±8.1) by the USP apparatus B. Microspheres had desirable
aerosol properties for pulmonary delivery (32), as indicated
by a MMAD for the P-rAg85B of 2.8±0.3 μm and fine
particle fraction of 68.9%±8.4.
DTH Response in Treated Animals
Currently, PPD is the only diagnostic tool to assess
exposure or infection with tuberculosis (20) and is also used
to assess the degree of immunity conferred by the only
approved tuberculosis vaccine BCG (21). Upon inoculation
into the skin of sensitized individuals, a DTH response is
evoked (22). However, DTH reaction does not correlate well
with vaccine-derived protection from infection (33). Thus, the
specific antigen used for vaccination can also be used in the
skin test to detect the systemic cell-mediated immunity. In this
study, PPD and rAg85B were used for detection of DTH
responses prior to challenge.
Six weeks after single-dose vaccination, animals vaccinated
with BCG (group 4, Fig. 1) exhibited DTH induration in
responses to PPD but no apparent response to i.d. rAg85B
solution. Animals vaccinated only with microparticle formula-
tions containing rAg85B (groups 1–3, Fig. 1) showed no
response to i.d. rAg85B solution or PPD. Likewise, in multi-
ple-dose groups, the homologous P-rAg85B and P-rAg85B-
TDB groups (Fig. 1, groups 5 and 6, respectively) did not
respond to PPD or rAg85B. In contrast, groups of BCG prime:
P-rAg85B boost, BCG, and BCG–BCG (groups 7, 8, and 9,
Fig. 1) responded to PPDwith induration diameters of 16.8±0.5,
17.7±0.9, and 18.3±0.7 mm, respectively, and did not respond to
i.d. rAg85B solution. A lack of DTH-induced response byMTB
culture filtrate protein has been observed previously in guinea
pigs, despite protective effects obtained in the lungs (34). Pais
et al. has also reported that the specificity of T cells involved in
the classical tuberculin reaction to PPD were different from
those involved in protective immunity (35). Consequently,
despite the apparent absence of immunity observed in some of
the experimental groups, as indicated by negative PPD test,
challenge studies were conducted in all groups.
Bacteriology and Histopathology
Single-Dose Studies
Figure 2 presents the bacteriology data for each of the
treatment groups with respect to the untreated control in
lungs and spleen.
Among lungs of animals receiving single-dose immuniza-
tion, BCG was the only treatment (log CFU=4.13±0.35) that
demonstrated a statistically significantly decrease in the bacte-
rial burden compared to untreated control (log CFU=5.42±
0.32). This observation was supported by the histopathological
observation of a smaller proportion of lung lobes containing
granulomas (Table I and Fig. 4b). Likewise, BCG was the only
Fig. 2. Bacterial burden in lungs and spleens of guinea pigs immu-
nized with single doses of the different formulations after challenge
with MTB H37Rv (BCG=BCG solution; PLGA ctl=blank micro-
particles; P-rAg85B=microparticles containing rAg85B; P-rAg85B-
TDB = microparticles containing rAg85B and adjuvant TDB
(average ± SD, n=6)
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treatment (log CFU 2.24±2.0) that demonstrated a statistically
significantly decrease in the bacterial burden in the spleens of
single-dose-immunized animals compared to untreated control
(log CFU=4.97±0.66). Histopathological analysis in these
groups also indicated that animals treated with BCG exhibited
a smaller proportion of white pulp affected by granulomas than
any other treatment (Table I, Fig. 5b).
Multiple-Dose Studies
Figure 3 presents the bacteriology data for each of the
treatment groups with respect to the untreated control in
lungs and spleen.
Under the experimental conditions of the present study,
vaccination strategies employing pulmonary homologous
immunizations with polymeric microparticles (P-rAg85B,
and P-rAg85B-TDB) were not effective in reducing bacterial
burden in the lungs of animals in these groups. In contrast,
regimens including BCG-prime appeared to be effective in
protecting animals against virulent challenge as evidenced by
bacterial counts in these groups. There was no significant
difference between BCG alone (log CFU=4.13±0.35), BCG–
P-rAg85B (log CFU=3.96±0.16), and BCG–BCG (log CFU=
4.04±0.31), but each was significantly smaller than untreated
controls (log CFU=5.42±0.32) P-rAg85B-P-rAg85B (log
CFU=5.78±0.27) and P-rAg85B-TDB-P-rAg85B-TDB
groups (log CFU=5.75±0.21). However, there were apparent
histopathological differences among these groups (Table I),
notably showing that animals in the BCG–P-rAg85B group
(Fig. 4f) had a smaller proportion of the lung lobes affected by
granulomas of smaller sizes than animals in the BCG (Fig. 4b)
and BCG–BCG groups (Fig. 4d). Furthermore, morphometric
analysis of lung tissue images confirmed that the total area of
lung tissue affected by granulomas was significantly smaller in
animals in the BCG–P-rAg85B group (Table II) than the BCG
or BCG–BCG groups. This suggests that BCG–P-rAg85B may
provide a greater protection than BCG alone or BCG–BCG.
The results from the statistical analysis of bacterial burden in
spleens were similar to those for lungs. There was no difference
in bacterial burden between BCG alone (log CFU 2.24±2.0),
BCG–P-rAg85B (log CFU=2.12±1.14) and BCG–BCG (log
CFU=0.9±1.47), but each of them was significantly lower than
untreated controls (log CFU=4.97±0.66), P-rAg85B-P-rAg85B
(log CFU=5.23±0.91), and P-rAg85B-TDB-P-rAg85B-TDB
(log CFU=5.50±0.42) groups. However, the histopathology of
spleens indicated that neither granulomas nor necrosis were
observed in the white pulp of the BCG–P-rAg85B group
(Fig. 5f), whereas in the BCG–BCG group (Fig. 5d), 30% of
the white pulp was affected by coalescing granulomas groups
(Table I). Conversely, no significant differences were noted by
morphometric analysis of spleen tissues of these groups
(Table II), possibly due to marked variations in granuloma sizes
and blending with lymphoid tissue in the spleen.
DISCUSSION
The proteins of the Antigen 85 complex have been
reported to be strongly recognized, during the course of
natural infection, in the same animal model in which they
Table I. Histopathology of Lung and Spleen Samples from Studied Guinea Pigs in Different Vaccination Groups (n=4)
Treatment Group % Lung lobe affected by granulomas Granuloma size % Granulomas affected
by caseous necrosis
Amount of caseous necrosis
A. Lung samples
Untreated Ctl 10–25 Med–large 10–50 Min–moderate
Single P-rAg85B 15–25 Med–large 10–30 Mild–moderate
P-rAg85B-P-rAg85B 10–20 Med–large 30–50 Mild
BCG 5–10 Small–med 0–10 None–minimal
BCG–P-rAg85B 5 Small 0–10 None–minimal
BCG–BCG 5–10 Medium 0–10 None–minimal
Treatment Group % White pulp affected by granulomas Granuloma size % Granulomas affected
by caseous necrosis
Amount of caseous necrosis
B. Spleen samples
Untreated Ctl 5–30 Med 50 Mild
Single P-rAg85B 10–30 Med 5 Minimal–mild
P-rAg85B-P-rAg85B 0–30 None–med 0–10 None–mild
BCG 5 Small–med 0 None
BCG–P-rAg85B 0 None 0 None
BCG–BCG 30 Coalescing 0 None
Fig. 3. Bacterial burden in lungs and spleens of guinea pigs immu-
nized with multiple doses of the different formulations after challenge
with MTB H37Rv (BCG=BCG solution; P-rAg85B=microparticles
containing rAg85B; P-rAg85B-TDB = microparticles containing
rAg85B and adjuvant TDB (average ± SD, n=6)
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promote a protective immune response if administered as a
pre-infection vaccine (36,37). In previous studies, Ag85B
showed to afford protection in mice (38) and guinea pigs (13)
when administered by parenteral routes. Pulmonary immuni-
zation capitalizes on the location and capacity for targeting
the antigen presenting cells (mainly alveolar macrophages) in
the lungs by engulfing the particles in appropriate size ranges.
Thus, it was hypothesized that pulmonary immunization with
P-rAg85B may result in the enhancement of the immune
response elicited in the lungs of vaccinated animals.
In the present study, a single-dose immunization with P-
rAg85B or P-rAg85B-TDB did not provide protection against
virulent challenge in guinea pigs. Given the complex design of
the present studies, there may be several reasons for this
outcome, including the dose of the antigen that was delivered
to the lungs of immunized animals, the immunization
regimen, and the animal species employed in the evaluation
of this vaccine. Studies conducted by Horwitz et al. demon-
strated protection in guinea pigs immunized with Ag85(13)
when compared to untreated animals, but it is important to
note that a control group of animals vaccinated with BCG
was not included in this study. Nevertheless, the protective
effect shown in Horwitz’s study may indicate that the dose of
Ag85B delivered in a single pulmonary immunization was
insufficient to elicit a protective immune response. Therefore,
multiple doses of Ag85B microparticles and different immu-
nization regimens were assessed, including BCG controls.
Fig. 4. Histopathology of lungs in studied guinea pigs (n=4). a Untreated control; b BCG solution positive
control; c Single-dose P-rAg85B; d BCG–BCG; e Multiple doses of P-rAg85B; f BCG–P-rAg85B (boost
administered by the pulmonary route)
Table II. Morphometric Analysis of Granulomas Affecting Lung and
Spleen Tissues of Guinea Pigs in Different Vaccination Groups
(average ± standard deviation, n=3–4)
Treatment Group





a Significantly smaller than other vaccination groups
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CD4 Th1 immunity is an important factor in protection
from tuberculosis. Memory CD4 T cells require restimulation
before acting on target cells to elicit an immune response
(39). Multiple homologous vaccinations should repeatedly
stimulate CD4 T memory cells specific for Ag85B epitopes.
However, in the present studies, no protection was observed
in the lungs or spleens by homologous strategies with multiple
doses of P-rAg85B and P-r-Ag85B-TDB, suggesting that the
limited number of epitopes from this antigen, compared to a
whole BCG bacterium, is insufficient alone to generate an
appropriate immune response. This was surprising, given the
results from a previous in vitro study in which P-rAg85B
microparticles elicited the production of IL2 that was two
orders of magnitude than the response elicited by soluble
rAg85B (14). These two results together suggest that the
ability of the immune system T cells to recognize antigens in
an in vitro bioassay and the ability to induce protection
following immunization in vivo do not necessarily correlate.
It may also indicate that the production of one cytokine
alone, IL2 in this case, is not a sufficient indicator, and the
response of other cytokines should also be considered.
Majlessi et al. (40) also arrived to the same conclusion
when they observed that a high level of IFN-γ, a relevant
cytokine marker of CD4 Th1 immunity, in the lung
parenchyma of mice immunized with Ag85A in an adeny-
late cyclase toxoid vector did not allow induction or
improvement of protection against MTB infection. These
studies also generated experimental evidence that despite
large IFN-γ and IL-2 cytokine responses with respect to IL-
4 and IL-5, protective effects were not seen in mice after
virulent MTB challenge (40).
In contrast, other studies have reported a modest success
with homologous vaccination employing Ag85B. Pioneer
studies by Pal et al. (41) reported a 1.1 and 1.2 log reduction
in bacterial burden of lungs and spleens, respectively, in
guinea pigs immunized subcutaneously with 120 μg of
extracellular proteins of MTB, twice or four times, 3 weeks
apart. In a subsequent study (13), the same group reported a
0.8 log reduction in lung bacterial burden after two or three
subsequent intradermal immunizations, 3 weeks apart, with
Fig. 5. Histopathology of spleens in studied guinea pigs (n=4). a Untreated control; b BCG solution
positive control; c single-dose P-rAg85B; d BCG–BCG; e multiple doses of P-rAg85B; f BCG–P-rAg85B
(boost administered by the pulmonary route)
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100 µg of Ag85B. However, neither of these studies included
control animals vaccinated with BCG for comparison.
Although Sugawara et al. (42) used a gene-based vaccine
instead of a peptide-based vaccine used in the present study,
they reported a 0.5 log reduction in bacterial burden after
three dermal administrations, 3 weeks apart, of 50 µg of
Ag85A DNA. Even though it may not have influenced the
outcome, another difference between the above described
studies and the present study is the MTB strain used for
bacterial challenge. While we employed H37Rv strain, Pal et
al. (41) and Horwitz et al. (13) employed Erdmand strain, and
Sugawara et al. (42) employed Kurono strain. Given the
results of studies performed by others described above,
despite the fact that multiple doses were administered, it is
likely that the dose of antigen delivered in microparticles by
pulmonary administration may not have been sufficient to
elicit an immune response. Whereas by parenteral admin-
istration, the entire dose is delivered to the animal, several
factors influence the pulmonary delivery of particles, includ-
ing encapsulation efficiency of the antigen, the site of lung
deposition, and potential for mucociliary clearance in the
lung. The 91.3% encapsulation efficiency for rAg85B in
PLGA particles was acceptable, but the amount of antigen
loaded in the microparticles is only 0.57–2.28% (w/w). Thus,
if considering the amount of microparticles delivered and the
percentage of antigen loaded in particles, 166.5 µg of rAg85B
in total would have been delivered to the lungs of animals
with the priming and boosting doses, which is a smaller dose
compared with those administered in the studies described
above (240–480 μg (41) and 200–300 µg (13), respectively).
An additional factor that may have influenced the protection
in immunized animals is the rate at which the antigen was
released from the polymeric particles. We have previously
shown that antigen release from microspheres was not
instantaneous with high initial burst of 58% of the rAg85B
in the first day, a cumulative 66% on day 3, 80% by day 20,
and completed 100% release by day 31 (14). Consequently, it
is likely that at any time point, a lower dose of antigen is
available to elicit an immune response in comparison with
other literature citations.
Besides the dose of antigen delivered to the lungs and its
rate of release, another factor that may have played a role in
the outcome of the present study is the animal model.
Compared to the existing mouse models, the guinea pig
model is known for being more “demanding” in the evalua-
tion of TB vaccines (43). A DNA vaccine encoding the
Ag85A protein was reported to yield protection comparable
to BCG in BALB/c and B6 mice (44) whereas it failed to
induce significant protection in Hartley guinea pigs under
conditions in which BCG was highly protective (34). The
susceptibility of each species to MTB may be a possible
explanation for this difference. The mouse is more resistant to
MTB infection, and different mouse strains have shown
different susceptibilities to MTB, whereas the guinea pig is
extremely susceptible to MTB and can be infected with one
or two virulent organisms (45).
Primary immunization with BCG establishes a favorable
immune response (balanced Th1/Th2 immunity) (46) that is
necessary for protection against tuberculosis. From the existing
reports in literature, it appears that in the stringent guinea pig
model, subunit vaccines have not been able to compete with the
protection provided by BCG (47), and some recombinant
vaccines have shown only a modest improvement compared to
BCG (43). Since the great majority of people living in TB-
endemic areas of the world are individuals already vaccinated
with BCG, a boosting strategy in this population would be a
better approach. However, homologous BCG boosting has
shown little or decreased efficacy (19), and a study has also
reported decreased survival in guinea pigs (48). Deaths in the
animals were attributed to disseminated lesions in several
organs, fibrosis, inflammation, and necrosis. These deleterious
effects have also been observed in animals after a booster dose
with MTB auxotrophs, which induced a stronger inflammatory
response and worsening of lung pathology (49). In contrast,
guinea pigs receiving the BCG–BCG prime-boost in the present
study appeared to be not adversely affected within the limits of
the experimental design.
Another possible vaccination strategy in the protection
against TB is to boost the waning memory immune response
from BCG with a fundamentally different vaccine, i.e., heterol-
ogous immunization (19,36). When the boost immunization,
different from the priming vaccine, is administered, the same
effector cells are quickly recruited, and the response is
augmented, while a different subset of effector cells may also
be stimulated to enhance the immunity. A non-replicating
vaccine capable of protecting as well as BCG, but without the
overall variability seen with BCG, would be of considerable
value (50). An advantage of delivering the vaccine directly to
the lungs is that the respiratorymucosal boost immunization can
lead to rapid activation and retention of Tcells located primarily
within the airway lumen, which play an important role in
protection from pulmonary MTB challenge (51).
In the past decade, several investigators have suggested
that relaying on “protection” alone may not be the best
criteria to screen potential TB vaccines and that survival/
pathology data in the guinea pig model may give a better idea
of the long-term effectiveness of a vaccine (34,49,50,52).
Studies have shown that bacillary burden at early time points
do not necessarily correlate with animal survival and that the
extent of pathology in involved organs may be a better
predictor of long-term disease outcome following MTB
infection (34,49,52). For example, an Ag85A-DNA vaccine
administered to guinea pigs did not induce a significant
reduction in the day-30 bacterial-load assay but showed
excellent long-term survival in immunized animals (52).
Baldwin et al. (34) suggested that the survival data in the
guinea pig model is model is influenced by the type and
severity of lesion produced in involved organs and the degree
of lymphocytic infiltration. Therefore, based on histopatho-
logical findings and morphometric analysis in the present
study, immunization with BCG–P-rAg85B appeared to
enhance the protection afforded by BCG alone and BCG–
BCG, even though the bacterial burden in the lungs and
spleens of animals receiving the vaccination regimen of
BCG–P-rAg85B was not statistically different from that of
animals receiving BCG and BCG–BCG vaccinations (possi-
bly due to a smaller dose of rAg85B delivered).
Although different administration routes were employed
and a smaller dose was delivered, the protective effect in
lungs with P-rAg85B pulmonary boosting immunization in
our study was comparable to that observed by Horowitz et al.
in response to 100 μg rAg85B administered intradermally as a
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boost following BCG priming (19). Perhaps the most
successful study of protection with the BCG prime was
followed by boosting with poxviruses expressing Ag85 (53).
Guinea pigs vaccinated with this regimen had a 100% survival
rate at 26 weeks compared to 40% after BCG alone and 0%
in saline controls.
In summary, polymeric microparticles containing
rAg85B were prepared in sizes suitable for delivery by
inhalation. Based on histopathological and morphometric
analysis, direct pulmonary immunization using these particles
enhanced the protection afforded by primary immunization
with BCG against TB infection in guinea pigs. Since a large
proportion of the population of the world has been immu-
nized with BCG as infants, an aerosol boost would be a
promising strategy to enhance and prolong the protective
immunity based on BCG-initiated immunity.
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